
Immunic Inc (IMUX) Stock Forecast & Price Target
Immunic Inc (IMUX) Analyst Ratings
Bulls say
Immunic Inc. has demonstrated promising clinical results in multiple sclerosis (MS) through its Phase 2 CALLIPER and EMPhASIS trials, showing significant reductions in disability worsening and improvements in MRI markers, indicating potential efficacy for its lead candidate, vidofludimus calcium. The company's focus on a selective approach to immunotherapy, particularly its small molecule products aimed at chronic inflammatory diseases, addresses critical unmet needs in the therapeutic landscape. Furthermore, the anticipated Phase 3 ENSURE trials, alongside supportive long-term safety and efficacy data, bolster investor confidence in Immunic's ability to successfully navigate late-stage development and capture market opportunities.
Bears say
Immunic Inc. faces significant financial challenges that contribute to a negative outlook on its stock. The company's recent capital raises, including a $5 million direct offering and a $65 million public offering, are overshadowed by a substantial cash burn of $20 million in R&D expenses and $6 million in general and administrative costs within a single quarter. Furthermore, risks associated with the potential failure of their developmental candidates to meet commercial revenue projections and the ongoing need for capital resources to sustain operations deepen the concerns regarding the company's future financial stability.
This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.
Immunic Inc (IMUX) Analyst Forecast & Price Prediction
Start investing in Immunic Inc (IMUX)
Order type
Buy in
Order amount
Est. shares
0 shares